Billionaire Mark Cuban (pictured) is calling for the breakup of large, vertically integrated health insurers, arguing that rising employer health care costs are quietly stifling hiring, wages and affordability.
Cuban is backing the bipartisan Break Up Big Medicine Act, which would force insurers to separate pharmacy benefit managers (PBMs), provider groups and drug distribution arms in an effort to improve transparency and competition.
According to a report from MSN, the billionaire contends that, for many companies, health benefits have effectively become a second payroll line, and that complex, multi-entity insurance structures are helping to drive those costs higher while obscuring where margins are made.
Cuban’s renewed push comes amid heightened public frustration with private health care, amplified by the December 2024 killing of UnitedHealthcare CEO Brian Thompson in New York.
The shooting, allegedly carried out by Luigi Mangione, drew national attention not only for its violence but for its symbolism, with ammunition reportedly bearing phrases critical of insurer practices. The case has become a grim backdrop to wider criticism of insurance industry consolidation and perceived abuses in claims handling.
The Break Up Big Medicine Act, which Cuban has publicly endorsed, would target insurer ownership of PBMs, provider groups and drug distribution networks. Supporters said such vertical integration will allow large health care conglomerates to control multiple points in the value chain, steer patients toward affiliated entities, and use internal transfer pricing to mask true costs. That can make it difficult to see whether savings from scale are being passed on or captured as profit, according to the report.
The legislative push is landing as regulators are already scrutinizing PBMs and integrated health care giants. Federal trade and antitrust authorities have opened inquiries into PBM business practices, including spread pricing and rebate structures, and state lawmakers have introduced their own transparency and licensing measures. Cuban’s campaign adds a high-profile, populist voice to that policy debate.
Supporters of the Break Up Big Medicine Act believe dismantling vertically integrated insurers could lower costs, improve transparency and free up corporate budgets for hiring and wage increases.
By forcing structural separation between insurers, PBMs, provider groups and drug distribution networks, they argue that it would be easier to see where money is made in the system and harder for related-party transactions to inflate reported medical costs.
Cuban frames the proposal as a market-driven fix: strip out what he views as anti-competitive structures, then let insurers, employers and independent providers compete on price and quality with clearer visibility into fees and margins. He has repeatedly linked employer health care spending to broader labor-market effects, arguing that if benefit costs did not rise so quickly, companies would have more room to boost pay or expand headcount instead of announcing layoffs or hiring freezes.
However, critics caution that aggressive breakup mandates could disrupt economies of scale and care coordination that some integrated organizations said help them manage chronic disease and fund investments in data and technology. They warn that unwinding large, complex groups could introduce short-term administrative costs and complexity, risks that might ultimately be borne by employers and members.
There were also open questions about scope. Depending on how definitions are written and enforced, long-standing integrated delivery systems that combine plans and providers under one parent could be swept into the same rules as publicly traded insurance conglomerates, forcing difficult choices about which assets to retain.
Cuban acknowledged that insurance structure is only one part of a wider cost problem that also involves hospital consolidation, drug pricing and demographics.
Even so, his support has helped make the Break Up Big Medicine Act a focal point in a broader conversation about employer costs, industry power and public trust in the wake of one of the most high-profile incidents in the sector’s recent history, according to the report.
Against this backdrop, the Mangione prosecutions continue to keep the industry in the headlines. Thompson’s killing in December 2024, outside a Midtown Manhattan hotel, shocked the corporate and health care worlds and has since been woven into broader public anger about insurance practices.
Mangione faces parallel state and federal cases -- a New York state murder trial and a separate federal case that includes interstate stalking and firearm-related charges. His state murder trial is now set to begin on Sept. 8, after being moved from its original June date, while his federal trial has been shifted from September to October. Judges in both jurisdictions have cited scheduling conflicts and the need for adequate preparation, but have resisted defense efforts to postpone proceedings into 2027.
Federal prosecutors have opposed lengthy delays, warning that major postponements could make it harder to secure witnesses and maintain public confidence in a timely resolution.
